Donald Weaver, M.D., Ph.D.

University of Toronto

Contact Information

Donald Weaver, M.D., Ph.D.
Toronto, Canada

Professional Information

Professor
University of Toronto

Education

Donald Weaver completed his MD at Queen’s University, Canada followed by an internal medicine internship at the Hôtel-Dieu and Kingston General Hospitals. He next completed clinical residency training in Neurology at the Queen Elizabeth II Health Sciences Centre, Dalhousie University, Canada; he also took additional training in behavioural neurology with a specific interest in dementia. He then returned to Queen’s University obtaining a Ph.D. in theoretical and organic chemistry, defending a dissertation on the applications of quantum mechanics and synthetic organic chemistry to neurologic drug design. In his first academic appointment, he taught chemistry and neurology at Queen’s University. While at Queen’s, he established the first memory disorders clinic at that institution and was Professor and Head of the Division of Neurology from 1998-2001. He subsequently moved to Dalhousie University as a Tier 1 Canada Research Chair in Neurodegenerative Diseases. While there he also became the inaugural Sobey Endowed Chair in Curative Approaches to Alzheimer’s Disease. He next relocated to the University of Toronto as a Tier 1 Canada Research Chair in Protein Misfolding and as the inaugural Director of the Krembil Research Institute.

Financial Disclosure

Member reports the following financial or other potential conflicts of interest:
[Last updated: Apr 16, 2023]

I am a co-founder of Treventis Corp. which is a startup biotech dedicated to the design and development of novel small molecule inhibitors of beta-amyloid and tau misfolding and oligomerization. Treventis is a spin-out from my academic laboratory. Currently, I am the Chief Medical Officer of Treventis.